NICK TILIACOS
CLINICAL RESEARCH CONSULTING

With 23 years of industry experience, including 21 years working as a SCRA/CRA, I’ve been fortunate enough to have worked across many therapeutic areas, in several capacities. I’ve worked primarily as a SCRA for mid to large-sized CRO’s in Australia and spent 9 years (from 2012 to 2021) working as a SCRA in North America. I've periodically taken on other roles such as a GCP auditor, staff mentor/trainer and PM and have led CRA teams, presented at bid defence meetings and contributed to the composition of study protocols and other essential trial document guidelines.

​

After obtaining a Bachelor of Science degree in Applied Biology/Biotechnology, I soon found myself working within the same department where I earned that qualification, as a Study Coordinator.  This all-encompassing role provided me the valuable experience I needed to transition into a CRA role, very soon after joining my first CRO.  The CRA role has certainly evolved over the years, and though I’ve dabbled in other positions, it’s always been the role that’s provided me with the most workplace satisfaction. 

​

I've been involved in all aspects of the clinical trial life-cycle, from feasibility and site evaluation for trial participation through to the monitoring of sites involved with late phase safety surveillance.

​

My therapeutic experience has included the following:

​

CNS Neurology

- Amyotrophic Lateral Sclerosis (ALS) (Phase II)

- Autism Spectrum Disorder (ASD) (Phase IIb)

- Traumatic Brain Injury (Phase I)
- Parkinson’s Disease (Phase IIb)
- Alzheimer’s Disease (Phase IIb)
- Epilepsy (Phase III)
- Male Erectile Dysfunction (Phase III)
- Major Depressive Disorder (Phase II)
- Post-Partum Depression (Phase III)
- Schizophrenia (Phase III)
- Erythromelalgia (Phase IIb)
- Relapsing Remitting Multiple Sclerosis (Phase II and III)
- Stroke (Phase II/IIb)
- Stroke, Non-Haemorrhagic (Phase II)
- Stroke, Acute Ischemic (Phase II)
- Urinary Incontinence (Phase III)

​

Oncology
- Solid Tumour Dose Escalation Studies (Phase I)
- Multiple Myeloma (Phase III)
- Acute Myeloid Lymphoma (Phase II)
- Chronic Lymphocytic Leukemia (Phase IIb)
- Prostate Cancer (Phase III)

​

Haematology
- Immune Thrombocytopenia Purpura (ITP) (Phase IIb)

​

Infectious Diseases/Gastrointestinal
- Clostridium difficile (Phase III)
- Influenza (Phase IV)

- COVID-19 Vaccines – protein and mRNA based (Phase I/IIa) 

​

Endocrine
- Diabetes Mellitus Type II (Phase III)

​

Rare/Other Disease Indications 

-  Phase I SAD/MAD healthy volunteer studies 

- Complement 3 Glomerulopathy (C3G)

- Autosomal Recessive Lamellar Ichthyosis (Phase II)
-  Pemphigus vulgaris (Phase III) 
-  WHIM syndrome (Phase II)
-  Fibrodysplasia Ossificans Progressiva (Phase II)
-  Autosomal Dominant Polycystic Kidney Disease (Phase III)

- Atopic Dermatitis (Phase Ib/II)

- Rheumatoid Arthritis (Phase Ib/II and III)  

​

​

​

​